Summary
- Profile Type
- Technology offer
- POD Reference
- TOSK20240610001
- Term of Validity
- 10 June 2024 - 10 June 2025
- Company's Country
- Slovakia
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A team of inventors from an established Slovak scientific and research institute and an established Slovak university has developed an innovative antimicrobial recombinant protein EN534-C with lytic properties against pathogenic strains of Streptococcus agalactiae. The protein EN534-C can be used mainly for the treatment, prevention or diagnosis of diseases caused by pathogenic bacteria Streptococcus agalactiae. The preferred cooperation type are commercial agreement or investment agreement.
- Full Description
-
Pathogenic bacteria Streptococcus agalactiae group B (GBS) cause severe diseases in humans and are primarily known to cause infections in pregnant women and children. According to the WHO, 15 - 45% of pregnant women suffer from Streptococcus agalactiae GBS colonization, while many of them are asymptomatic. GBS is the leading cause of neonatal morbidity and mortality. In children, the infection caused by GBS can lead to blood poisoning (septicemia), inflammation or damage to the lungs, as well as to neonatal meningitis and brain damage. In adults, especially in those with a weakened immune system often due to other diseases, the infection caused by GBS can lead to other types of severe diseases, such as streptococcal toxic shock syndrome, septicemia, urinary tract infections, pneumonia, meningitis and endocarditis, and also necrotizing fascitis.
A team of inventors from an established Slovak scientific and research institute and an established Slovak university has developed an innovative antimicrobial recombinant protein EN534-C with lytic properties against pathogenic strains of Streptococcus agalactiae. EN534-C specifically binds to the substrate ligand of the bacteria peptidoglycan via the binding domain, and subsequently, by the enzymatic activity of the lytic domains, the chemical bond in the peptidoglycan of the bacterial cell wall is cleaved. EN534-C is characterized by lytic activity against a wider spectrum of Gram-positive bacteria: Streptococcus agalactiae GBS, Paenibacillus larvae, Bacillus subtilis, Enterococcus faecalis, and Gram-negative bacteria Pseudomonas aeruginosa and Escherichia coli, while at the same time it does not act lytically against Lactobacillus jensenii. The protein EN534-C can be used mainly for the treatment, prevention or diagnosis of diseases caused by pathogenic bacteria Streptococcus agalactiae.
The institutions are looking for a partner to cooperate with via commercial agreement or investment agreement. - Advantages and Innovations
-
• high specificity,
• avoidance of negative side effects associated with the administration of antibiotics,
• low probability of bacterial resistance,
• reduction of risk of developing resistance against therapeutic phages,
• the isolated protein is thermally stable in the temperature range from 20°C to 37°C and can be isolated at room temperature; this also reduces the energy requirements for the recombinant protein isolation in industrial use. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 17: Partnerships to achieve the Goal
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The protein EN534-C can be used mainly for the treatment, prevention or diagnosis of diseases caused by pathogenic bacteria Streptococcus agalactiae. EN534-C can be applied in the case of multi-resistant streptococcal infections, not only in pregnant women and newborns, but also in other adults. The preparation of endolysin EN534-C also has a great potential in treatment of vaginal bacteraemia and urogenital infections, and in applications and treatment of non-healing wounds and venous ulcers infected with streptococci. EN534-C also has a potential for use in the veterinary field, e.g. for the treatment of mastitis or superficial infections in animals. Isolated preparation of the endolysin can be also used for decontamination of surfaces (in connection with the occurrence of streptococci) and as a surface cleaning agent.
The institute and the Slovak university are looking for a partner to cooperate with via commercial agreement (a partner for licensing of this technology is sought,) or investment agreement (an investor to further develop this technology is sought or a partner to sell this technology to is sought). - Type and Size of Partner
- SME 50 - 249
- Big company
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001007 - Other diagnostic
- Targeted countries
- All countries